219 related articles for article (PubMed ID: 37465637)
1. Tolerability and Efficacy of a 10:25 Preparation of Δ9-Tetrahydrocannabinol and Cannabidiol for Treatment of Chronic Back or Neck Pain: A Multiple-Dose Escalation Study.
Glare P; Chye R; Bloch M; Arya M; Moore A; Montgomery J
Med Cannabis Cannabinoids; 2023; 6(1):66-76. PubMed ID: 37465637
[TBL] [Abstract][Full Text] [Related]
2. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
3. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
4. Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.
Clarke S; Butcher BE; McLachlan AJ; Henson JD; Rutolo D; Hall S; Vitetta L
PLoS One; 2022; 17(10):e0270543. PubMed ID: 36240167
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study.
Bonomo Y; Norman A; Collins L; O'Neill H; Galettis P; Trinca J; Strauss N; Martin J; Castle D
Pain Ther; 2022 Mar; 11(1):171-189. PubMed ID: 34921662
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
7. Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study.
Huntsman RJ; Tang-Wai R; Alcorn J; Vuong S; Acton B; Corley S; Laprairie R; Lyon AW; Meier S; Mousseau DD; Newmeyer D; Prosser-Loose E; Seifert B; Tellez-Zenteno J; Huh L; Leung E; Major P
Front Neurol; 2019; 10():716. PubMed ID: 31333569
[No Abstract] [Full Text] [Related]
8. Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.
Peters EN; Mosesova I; MacNair L; Vandrey R; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
J Anal Toxicol; 2022 May; 46(5):528-539. PubMed ID: 33848338
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
Johnson JR; Burnell-Nugent M; Lossignol D; Ganae-Motan ED; Potts R; Fallon MT
J Pain Symptom Manage; 2010 Feb; 39(2):167-79. PubMed ID: 19896326
[TBL] [Abstract][Full Text] [Related]
10. Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.
Jacobs DS; Kohut SJ; Jiang S; Nikas SP; Makriyannis A; Bergman J
Exp Clin Psychopharmacol; 2016 Oct; 24(5):320-330. PubMed ID: 27690502
[TBL] [Abstract][Full Text] [Related]
11. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
12. Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.
de Vries M; Van Rijckevorsel DC; Vissers KC; Wilder-Smith OH; Van Goor H
Br J Clin Pharmacol; 2016 Mar; 81(3):525-37. PubMed ID: 26505163
[TBL] [Abstract][Full Text] [Related]
13. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
Hoggart B; Ratcliffe S; Ehler E; Simpson KH; Hovorka J; Lejčko J; Taylor L; Lauder H; Serpell M
J Neurol; 2015 Jan; 262(1):27-40. PubMed ID: 25270679
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry.
Ueberall MA; Essner U; Mueller-Schwefe GH
J Pain Res; 2019; 12():1577-1604. PubMed ID: 31190969
[No Abstract] [Full Text] [Related]
15. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
[TBL] [Abstract][Full Text] [Related]
16. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
[TBL] [Abstract][Full Text] [Related]
17. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of escalating cannabinoid doses in healthy cats.
Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD
Chicoine A; Illing K; Vuong S; Pinto KR; Alcorn J; Cosford K
Front Vet Sci; 2020; 7():583404. PubMed ID: 33134364
[No Abstract] [Full Text] [Related]
20. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
